OTCBB ALERTS

[Mandroid]

Lifeline Biotechnologies, Inc. LBTN) today
announced that the Company has taken the next step in their strategy to up
list to a higher exchange such as the OTC:BB and/or NASDAQ by posting their
2003 audited and 2004 unaudited financial and information statements on
Pinksheets.com. This information will also be made available on Lifeline
Biotechnologies' website, www.lbtn.com.





"The eventual up listing to the OTC:BB or a higher exchange is one of the
main business strategies of Lifeline Biotechnologies, Inc. Our
shareholders' value in Lifeline Biotechnologies is expected to increase as
we continue to execute our business plan, by taking the necessary steps of
full financial disclosure," stated Jim Holmes, CEO of Lifeline
Biotechnologies.



Lifeline Biotechnologies recently announced that the Company is actively
pursuing merger and acquisition candidates. Lifeline Biotechnologies is
targeting companies in the medical, nutraceutical, and energy industries.



About Lifeline Biotechnologies, Inc.



Lifeline Biotechnologies, Inc. is a company with innovative medical
technologies committed to the improvement of the quality of life through
exceptional health care systems. These technologies focus on prevention,
early detection, diagnosis and quick recovery of a number of disease
conditions. The company's technologies which assist practicing physicians
in the delivery of quality medical care. The MastaScope(TM) is used to
assist in the early detection of cancer and other abnormalities of the
breast. The MastaScope(TM) has completed development and has entered the
marketplace internationally. The First Warning System(TM) for assisting in
the early detection of breast cancer and the OvaScope(TM) for assisting in
the early detection of ovarian cancer are continuing to be developed by the
company. More information is available at the company's website:
www.lbtn.com.



Safe Harbor



This release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 27E of the Securities
Act of 1934. Statements contained in this release that are not historical
facts may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected or
suggested herein due to certain risks and uncertainties including, without
limitation, ability to obtain financing and regulatory and shareholder
approval for anticipated actions.



Contact:
For Lifeline Biotechnologies, Inc.
Big Apple Consulting USA, Inc.
Investor Relations,
407-884-0444
1-866-THE-APPL(E)